Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the H.C. Wainwright & Co. 24^th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Dwight Egan will present on the company’s progress and upcoming Co-Dx PCR Home Diagnostic Platform. The presentation is scheduled for September 13 at 8:30 AM ET, accessible for registered institutional investors. One-on-one meetings with H.C. Wainwright representatives will also be available.

SALT LAKE CITY, Sept. 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 24^th Annual Global Investment Conference, being held virtually and in-person on September 12-14 in New York City, New York.

Dwight Egan, Company CEO, will be conducting a presentation discussing recent and expected Company progress along with its forthcoming Co-Dx PCR Home Diagnostic Platform. The presentation can be accessed by clicking here or through the Events and Webcasts section of the Co-Diagnostics website on September 13, 2022 at 8:30 AM Eastern Time, for institutional investors and industry professionals who have registered for the event. 

The Company will also be participating in one-on-one meetings, which can be arranged with H.C. Wainwright representatives.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-hc-wainwright-24th-annual-global-investment-conference-on-september-12-14-2022-301621851.html

SOURCE Co-Diagnostics

FAQ

When is Co-Diagnostics presenting at the H.C. Wainwright conference?

Co-Diagnostics will present on September 13, 2022, at 8:30 AM Eastern Time.

What will Co-Diagnostics discuss during the conference?

Co-Diagnostics will discuss its recent progress and the upcoming Co-Dx PCR Home Diagnostic Platform.

Where is the H.C. Wainwright conference being held?

The H.C. Wainwright & Co. conference is being held in New York City and virtually from September 12-14, 2022.

How can I watch Co-Diagnostics' presentation?

The presentation can be accessed via the Co-Diagnostics website or by clicking the provided link in their press release.

Who is the CEO of Co-Diagnostics?

The CEO of Co-Diagnostics is Dwight Egan.